See more : Daan Gene Co., Ltd. (002030.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Klaria Pharma Holding AB (publ.) (KLAR.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Klaria Pharma Holding AB (publ.), a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Play Magnus AS (PMGMF) Income Statement Analysis – Financial Results
- General Oyster, Inc. (3224.T) Income Statement Analysis – Financial Results
- Federal National Mortgage Association (FNMA) Income Statement Analysis – Financial Results
- Baroque Japan Limited (3548.T) Income Statement Analysis – Financial Results
- Hamilton Insurance Group, Ltd. (HG) Income Statement Analysis – Financial Results
Klaria Pharma Holding AB (publ.) (KLAR.ST)
About Klaria Pharma Holding AB (publ.)
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 5.87M | 6.11M | 7.22M | 4.22M | 649.00K | 2.28M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 9.00K | 0.00 | 10.97M | 13.43M | 0.00 | 9.58M | 0.00 | 9.00K | 0.00 | 301.07K |
| Gross Profit | -9.00K | 5.87M | -4.85M | -6.21M | 4.22M | -8.93M | 2.28M | -9.00K | 0.00 | -301.07K |
| Gross Profit Ratio | 0.00% | 100.00% | -79.40% | -86.04% | 100.00% | -1,375.96% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.45M | 51.36M | 57.38M | 41.22M | 16.86M | 22.34M | 9.50M | 10.00M | 2.85M | 0.00 |
| General & Administrative | 9.21M | 7.86M | 7.55M | 6.47M | 6.65M | 3.07M | 3.06M | 2.59M | 1.94M | 0.00 |
| Selling & Marketing | 1.23M | 2.29M | 2.31M | 1.83M | 1.82M | 2.43M | 2.36M | 2.25M | 1.12M | 0.00 |
| SG&A | 10.44M | 10.16M | 9.86M | 8.29M | 8.47M | 5.50M | 5.42M | 4.84M | 3.06M | 17.99K |
| Other Expenses | 0.00 | -203.00K | 13.74M | -611.00K | -1.00K | -521.00K | -372.00K | -358.00K | -312.00K | 0.00 |
| Operating Expenses | 14.88M | 61.31M | 80.97M | 48.90M | 25.33M | 27.31M | 14.55M | 14.48M | 5.59M | 301.07K |
| Cost & Expenses | 14.89M | 61.31M | 80.97M | 48.90M | 25.33M | 27.31M | 14.55M | 14.48M | 5.59M | 602.14K |
| Interest Income | 0.00 | 3.00K | 1.00K | 2.00K | 3.00K | 19.00K | 76.00K | 8.00K | 0.00 | 0.00 |
| Interest Expense | 3.78M | 7.84M | 3.17M | 2.56M | 1.35M | 2.00K | 6.00K | 72.00K | 1.00K | 0.00 |
| Depreciation & Amortization | 9.00K | 11.03M | 10.97M | 13.43M | 10.09M | 9.58M | 9.58M | 9.00K | 5.59M | 0.00 |
| EBITDA | -14.77M | -44.78M | -39.41M | -35.42M | -11.05M | -17.73M | -11.99M | -14.54M | -1.00K | -602.14K |
| EBITDA Ratio | 0.00% | -763.12% | -1,144.44% | -490.51% | -261.71% | -2,731.12% | -526.59% | 0.00% | 0.00% | 0.00% |
| Operating Income | -14.68M | -54.97M | -50.11M | -48.74M | -21.09M | -27.29M | -12.27M | -14.48M | -5.59M | -602.14K |
| Operating Income Ratio | 0.00% | -936.84% | -819.85% | -675.04% | -499.46% | -4,205.39% | -539.38% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -3.76M | -8.22M | -3.44M | -2.67M | -1.38M | 7.00K | 268.00K | -75.00K | -1.00K | 0.00 |
| Income Before Tax | -18.44M | -63.66M | -53.55M | -51.41M | -22.49M | -27.31M | -12.01M | -14.55M | -5.59M | 0.00 |
| Income Before Tax Ratio | 0.00% | -1,084.82% | -876.06% | -712.05% | -532.61% | -4,207.40% | -528.09% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -57.00K | 117.00K | -11.00K | 29.00K | 1.35M | 13.00K | -257.00K | 75.00K | -5.59M | 0.00 |
| Net Income | -35.78M | -63.77M | -53.53M | -51.44M | -23.84M | -27.31M | -12.01M | -14.55M | -5.59M | 0.00 |
| Net Income Ratio | 0.00% | -1,086.81% | -875.88% | -712.45% | -564.60% | -4,207.40% | -528.09% | 0.00% | 0.00% | 0.00% |
| EPS | -0.36 | -1.10 | -0.97 | -1.11 | -0.72 | -0.83 | -0.37 | -0.45 | -0.30 | 0.00 |
| EPS Diluted | -0.36 | -1.10 | -0.97 | -1.11 | -0.72 | -0.83 | -0.37 | -0.45 | -0.27 | 0.00 |
| Weighted Avg Shares Out | 99.40M | 58.10M | 55.25M | 46.21M | 33.23M | 32.84M | 32.51M | 31.99M | 18.46M | 50.00K |
| Weighted Avg Shares Out (Dil) | 100.80M | 58.10M | 55.25M | 46.21M | 33.23M | 32.84M | 32.51M | 31.99M | 20.87M | 50.00K |
Source: https://incomestatements.info
Category: Stock Reports